As previously reported in heavily-pretreated breast cancer patients, hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-positive subgroups responded to alisertib treatment, but minimal activity was seen in the triple-negative subtype (Melichar et al., 2015). The gene discussed is ERBB2; the disease is breast cancer.